PDCD1 and neoplasm: This is further supported by combinatorial PD-1 mAb coupled LSD1-inhibition therapy in exhibiting superior reduced tumor progression/tumor metastasis, reduced CD4+/CD8+ T cell ratio, and increased nodal CD3+/CD8+ T cell populations.